Lipid-lowering LPL variants were associated with decreased risks of hypertension, type 2 diabetes, nonalcoholic fatty liver disease, and bladder cancer (q<0.05). This evidence concerns the gene LPL and metabolic dysfunction-associated steatotic liver disease.